Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2− Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy
Conclusion
This retrospective claims database analysis of elderly women with HR+/HER2− mBC in the United States showed that everolimus-based therapy was associated with significantly lower all-cause, BC-related, and AE-related medical services costs and less use of healthcare resources compared with chemotherapy.
Funding
Novartis.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Databases & Libraries | Drugs & Pharmacology | Hormones | Study | Women | Xeloda